Klogene Therapeutics, Inc.

Biotech · Defunct

Small molecule therapeutics that cross the blood-brain barrier and increase Klotho gene expression to treat Alzheimer's disease

klogene.com →
Grants
$2.0M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
5
0 granted · 5 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A Novel Neuroprotective Therapy For Alzheimer's Disease$1,490,552
Federal grantDepartment of Health and Human Services · Phase II · A Novel Neuroprotective Therapy For Alzheimer’s Disease$468,418
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1759SERINA THERAPEUTICS INC—$34M
1760Iterative Therapeutics Inc.——
1761Rhodium Scientific, LLC——
1762Klogene Therapeutics, Inc.——
1763TellBio, Inc.—$11M
1764Trilo Therapeutics, Inc.——
1765Phaeno Inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 5
  • Klotho Is Neuroprotective In The Superoxide Dismutase (SOD1G93A) Mouse Model Of Alsapplication
  • Increasing Gene Expressionapplication
  • Dna Binding Proteins And Uses Thereofapplication
  • Increasing Gene Expressionapplication
  • Compositions And Methods For Modulating Gene Expressionapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.